[go: up one dir, main page]

AR015241A1 - VITRONECTINE RECEPTOR ANTAGONISTS PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents

VITRONECTINE RECEPTOR ANTAGONISTS PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.

Info

Publication number
AR015241A1
AR015241A1 ARP990101019A ARP990101019A AR015241A1 AR 015241 A1 AR015241 A1 AR 015241A1 AR P990101019 A ARP990101019 A AR P990101019A AR P990101019 A ARP990101019 A AR P990101019A AR 015241 A1 AR015241 A1 AR 015241A1
Authority
AR
Argentina
Prior art keywords
alkyl
het
cycloalkyl
co2rg
crg2
Prior art date
Application number
ARP990101019A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR015241A1 publication Critical patent/AR015241A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Antagonistas del receptor de vitronectina de formula (I) que son utiles en el tratamiento de osteosporosis: (I) en la que R* es II, X es CRR, NR o S;Y es CRR, NR o S; A es H, halo, ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, -S(O)rCF3, -CO2Rg, -CORg, -CONRg2, -alquilo C1-6, -alquil C0-6-Ar, -alquil C0-6-Het,-alquil C0-6-cicloalquilo C3-6, -S(O)kRg,o CH2N(Rf)2;R1 es-alquil C0-6-Het,-alquil C0-6-Ar, -alquilo C1-6, -H, -CN, -CH=CH2, -C=CH o -S(0)kRg; R2 es III, W es-(CHRg)a-U-(CHRg)b-; U está ausente o esCO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg, CR9(ORk)CRg2, CRgCRg(ORk), C(O)CRg2, CRg2C(O), CONRi, NRiCO, OC(O), C(O)O,C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2, N=N, NRgNRg, NRgNRg2, CRg2CRg, CRg2O, OCRg2, C=C, CRg=CRg, Ar o Het; G es NRe, su o; Rg es H, alquiloC1-6, cilcoalquil C3-7-alquilo C0-6 o Ar-alquilo C0-6; Rk es Rg, -C(O)Rg, o -C(O)ORf; Ri es H, alquilo C1-6, Het-alquilo C0-6, cicloalquil C3-7-alquilo C0-6,Ar-alquil C0-6 o alquilo C1-6 sustituido con uno a tres grupos seleccionados entre halogeno, CN, NRg2, ORg, SRg, CO2Rg y CON(Rg)2; Rf es H, alquilo C1-6 oAr-alquilo C0-6; Re es H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6, cicloalquilo C3-7-alquilo C0-6 o (CH2)kCO2Rg; Rb y Rc se seleccionanindependientemente entreH, alquilo C1-6, Ar-alquil C0-6, Het-alquilo C0-6, cicloalquil C3-6-alquilo C0-6, halogeno, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2,CO(NRf)2,CH2N(Rf)2,o Rb y Rc están unidos entre sí para formar un anillo carbocíclico o heterocíclico,aromático o no aromático,de 5 o 6 miembros,opcionalmentesustituido hasta con 3 sustituyentes elegidos entre halogeno, CF3, alquilo C1-4, ORf, S(O)kRf, CORf, OH, NO2, N/Rf)2, CON(Rf)2 y CH2N(Rf); o metilendioxi; Q1,Q2, Q3 y Q4 son independientemente N o C-Ry, siempre que no más de uno de Q1,Q2,Q3 y Q4 sea N; R es H, alquilo C1-6, Ar-alquilo C0-6 o cicloalquil C3-6-alquilo C0-6; R es R, -C(O)R o -C(O)OR; Ry es H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF3,-CF3S(O)r-, -CO2Rg o -CONRg2, o alquilo C1-6 opcionalmentesustituido con halo ORg, SRg,-CN,-NRgR, -NO2,-CF3,RS(O)r-, -CO2Rg, -CORg, o -CONRg2; a es 0, 1 o 2; b es 0, 1 o 2; k es 0, 1 o 2; r es 0, 1 o 2; s es 0, 1 oVitronectin receptor antagonists of formula (I) that are useful in the treatment of osteosporosis: (I) in which R * is II, X is CRR, NR or S; Y is CRR, NR or S; A is H, halo, ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, -S (O) rCF3, -CO2Rg, -CORg, -CONRg2, -C1-6 alkyl, -C0-6 alkyl -Ar, -C0-6-Het alkyl, -C0-6 alkyl-C3-6 cycloalkyl, -S (O) kRg, or CH2N (Rf) 2; R1 is -C0-6-Het alkyl, -C0 alkyl 6-Ar, -C 1-6 alkyl, -H, -CN, -CH = CH2, -C = CH or -S (0) kRg; R2 is III, W is- (CHRg) a-U- (CHRg) b-; U is absent or esCO, CRg2, C (= CRg2), S (O) k, O, NRg, CRgORg, CR9 (ORk) CRg2, CRgCRg (ORk), C (O) CRg2, CRg2C (O), CONRi, NRiCO, OC (O), C (O) O, C (S) O, OC (S), C (S) NRg, NRgC (S), S (O) 2NRg, NRgS (O) 2, N = N , NRgNRg, NRgNRg2, CRg2CRg, CRg2O, OCRg2, C = C, CRg = CRg, Ar or Het; G is NRe, his or; Rg is H, C1-6 alkyl, C3-7 cylcoalkyl- C0-6 alkyl or Ar-C0-6 alkyl; Rk is Rg, -C (O) Rg, or -C (O) ORf; Ri is H, C1-6 alkyl, Het-C0-6 alkyl, C3-7 cycloalkyl, C0-6 alkyl, Ar-C0-6 alkyl or C1-6 alkyl substituted with one to three groups selected from halogen, CN, NRg2 , ORg, SRg, CO2Rg and CON (Rg) 2; Rf is H, C1-6 alkyl or Ar-C0-6 alkyl; Re is H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl or (CH2) kCO2Rg; Rb and Rc are independently selected from H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, halogen, CF3, ORf, S (O) kRf, CORf, NO2, N (Rf) 2, CO (NRf) 2, CH2N (Rf) 2, or Rb and Rc are joined together to form a carbocyclic or heterocyclic ring, aromatic or non-aromatic, of 5 or 6 members, optionally substituted up to 3 substituents chosen from halogen, CF3, C1-4 alkyl, ORf, S (O) kRf, CORf, OH, NO2, N / Rf) 2, CON (Rf) 2 and CH2N (Rf); or methylenedioxy; Q1, Q2, Q3 and Q4 are independently N or C-Ry, provided that no more than one of Q1, Q2, Q3 and Q4 is N; R is H, C1-6 alkyl, Ar-C0-6 alkyl or C3-6 cycloalkyl-C0-6 alkyl; R is R, -C (O) R or -C (O) OR; Ry is H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, -CF3S (O) r-, -CO2Rg or -CONRg2, or C1-6 alkyl optionally substituted with halo ORg, SRg, -CN, -NRgR, -NO2, -CF3, RS (O) r-, -CO2Rg, -CORg, or -CONRg2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; r is 0, 1 or 2; s is 0, 1 or

ARP990101019A 1998-03-10 1999-03-10 VITRONECTINE RECEPTOR ANTAGONISTS PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. AR015241A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
AR015241A1 true AR015241A1 (en) 2001-04-18

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101019A AR015241A1 (en) 1998-03-10 1999-03-10 VITRONECTINE RECEPTOR ANTAGONISTS PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.

Country Status (24)

Country Link
EP (1) EP1061921A4 (en)
JP (1) JP2002506033A (en)
KR (1) KR20010041812A (en)
CN (1) CN1299282A (en)
AP (1) AP2000001898A0 (en)
AR (1) AR015241A1 (en)
AU (1) AU758498B2 (en)
BG (1) BG104824A (en)
BR (1) BR9908636A (en)
CA (1) CA2323208A1 (en)
CO (1) CO5080762A1 (en)
DZ (1) DZ2741A1 (en)
EA (1) EA200000921A1 (en)
HU (1) HUP0101143A3 (en)
ID (1) ID26223A (en)
IL (1) IL138245A0 (en)
NO (1) NO20004503L (en)
OA (1) OA12189A (en)
PE (1) PE20000323A1 (en)
PL (1) PL342881A1 (en)
SK (1) SK13292000A3 (en)
TR (1) TR200002625T2 (en)
UY (2) UY25421A1 (en)
WO (1) WO1999045927A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (en) * 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitors of the integrin alphavbeta¶3¶
DE19939981A1 (en) * 1999-08-24 2001-03-01 Merck Patent Gmbh New inhibitors of the integrin alphavß3
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
FR2808798A1 (en) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
EP1289960A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
RU2367661C2 (en) * 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Thiazole derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CN101228129A (en) 2005-04-20 2008-07-23 詹森药业有限公司 N-oxidation method of fluoropyridine N-oxide thrombin modulators and nitrogen-containing heteroaryl compounds
HUE041418T2 (en) 2013-08-29 2019-05-28 Kyoto Pharma Ind Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism
PT3050878T (en) 2013-09-24 2021-12-02 Fujifilm Corp Novel nitrogen-containing compound or salt thereof, or metal complex thereof
CA2950390C (en) 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906103A1 (en) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Vitronectin receptor antagonists
JP2000502708A (en) * 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist

Also Published As

Publication number Publication date
IL138245A0 (en) 2001-10-31
KR20010041812A (en) 2001-05-25
BR9908636A (en) 2002-01-08
NO20004503D0 (en) 2000-09-08
EA200000921A1 (en) 2001-04-23
ID26223A (en) 2000-12-07
CA2323208A1 (en) 1999-09-16
HUP0101143A2 (en) 2001-08-28
AU758498B2 (en) 2003-03-20
WO1999045927A1 (en) 1999-09-16
PE20000323A1 (en) 2000-05-24
HUP0101143A3 (en) 2002-12-28
CN1299282A (en) 2001-06-13
EP1061921A4 (en) 2005-03-30
TR200002625T2 (en) 2000-12-21
UY25519A1 (en) 1999-12-13
SK13292000A3 (en) 2001-06-11
BG104824A (en) 2001-05-31
UY25421A1 (en) 2001-07-31
JP2002506033A (en) 2002-02-26
EP1061921A1 (en) 2000-12-27
AP2000001898A0 (en) 2000-09-30
CO5080762A1 (en) 2001-09-25
DZ2741A1 (en) 2003-09-08
OA12189A (en) 2006-05-09
NO20004503L (en) 2000-10-10
PL342881A1 (en) 2001-07-16
AU2903399A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
AR015241A1 (en) VITRONECTINE RECEPTOR ANTAGONISTS PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
PA8546601A1 (en) NEW INDOL DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEIVER
PA8586401A1 (en) 4-PIPERAZINILBENCENOSULFONILINDOLES AND USE OF THE SAME
PA8547901A1 (en) 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY
AR011229A1 (en) ADENOSINE-DERIVED COMPOUNDS ANTAGONISTS IN THE AI ADENOSINE RECEPTOR, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN MEDICINE.
ES2617619T3 (en) Drug combinations comprising a DGAT inhibitor and a PPAR agonist
PE20040832A1 (en) DERIVATIVES OF INDOLIL PIRAZINONE
PE10499A1 (en) VITRONECTIN RECEPTOR ANTAGONISTS
AR050913A1 (en) COMPOUNDS DERIVED FROM THIAZOLPIRIDINE AS GLUCOQUINASE ACTIVATORS; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN MEDICINES FOR THE TREATMENT OF TYPE II DIABETES
DE60318030D1 (en) PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOSIS
DK1404317T3 (en) 5-Halogen tryptamine derivatives for use as ligands of 5-HT6 and / or 5-HT7 serotonin receptors
PE20010009A1 (en) DERIVATIVES OF PHENYL - AND PYRIDINYL AS ANTAGONISTS OF THE NEUROQUININ 1 RECEPTOR
HRP20000896B1 (en) Adenosine derivatives
AR033791A1 (en) COMPOUNDS OF OXAMIC ACIDS AND DERIVATIVES AS LINKS OF THYROID RECEPTORS, THEIR USE. COMPOSITION AND CASE CONTAINING IT
AR004735A1 (en) CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
AR016433A1 (en) PROCEDURE FOR THE TREATMENT OF IMPOTENCE AND COMPOSITIONS.
ES2094843T3 (en) BENCISOTIAZOL- AND BENCISOXAZOL-3-CARBOXAMIDES, A PROCEDURE FOR THEIR PREPARATION AND USE AS ANTIPSYCHOTIC MEDICINES.
RU2007138937A (en) 1-BENZYLINDOL-2-CARBOXAMIDE DERIVATIVES
PE20081192A1 (en) PAIN TREATMENT
CR8505A (en) DERIVATIVES OF (3-OXO-3,4-DIHIDROQUINOXALIN-2-IL-AMINO) -BENZAMIDE AND RELATED COMPOUND, AS INHIBITORS OF GLUCOGENO FOSFORILASA FOR THE TREATMENT OF DIABETES AND OBESITY
AR021354A1 (en) PROCEDURE FOR THE PREPARATION OF A QUINOLINE DERIVATIVE COMPOUND AND A PROCEDURE TO PREPARE A PHARMACEUTICAL COMPOSITION
ES2054304T3 (en) PHENYLETHANOLAMINOMETHYLETHETRALINS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
CO4771153A1 (en) PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLE ETHER COMPOUNDS AS ANTAGONISTS OF THE SUBSTANCE P.
ES2095277T3 (en) 6,7-DIHIDRO-3-FENIL-1,2-BENZOISOXAZOL-4 (5H) -ONAS AND -OLES, A PROCEDURE FOR THEIR PREPARATION AND USE AS MEDICINES.
HRP20080274T3 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri

Legal Events

Date Code Title Description
FA Abandonment or withdrawal